{"preliminary_commentary":{"by_channel":{"youtube":4,"x_thread":3,"podcast":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04277637\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"BGB-11417-101","nct_id":"NCT04277637","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bgb-11417-101-nct04277637. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) or transformed NHL, mantle cell lymphoma (MCL); Waldenströms macroglobulinemia (WM); and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) will receive oral sonrotoclax evaluated as monotherapy.","label":"Sonrotoclax Monotherapy Dose Finding: Part 1","type":"EXPERIMENTAL"},{"description":"Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; CLL/SLL with low tumor burden or low creatine clearance; CLL/SLL with without high tumor burden or low creatine clearance will receive oral sonrotoclax at the RP2D dose to further define the safety profile.","label":"Sonrotoclax Monotherapy Expansion Cohorts: Part 2","type":"EXPERIMENTAL"},{"description":"Participants with R/R MCL, R/R or treatment-naïve (TN) CLL/SLL will receive oral sonrotoclax in combination with zanubrutinib.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Finding: Part 3","type":"EXPERIMENTAL"},{"description":"Participants with R/R indolent NHL including FL, MZL; aggressive NHL including DLBCL, transformed NHL; R/R MCL; R/R or treatment-naïve (TN) CLL/SLL will receive oral sonrotoclax in combination with zanubrutinib at an RP2D dose to further define the safety profile.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 4","type":"EXPERIMENTAL"},{"description":"Participants with treatment naïve CLL/SLL will receive oral sonrotoclax in combination with obinutuzumab without and with zanubrutinib.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Escalation: Part 5","type":"EXPERIMENTAL"},{"description":"Participants with treatment naïve CLL/SLL will receive oral sonrotoclax in combination with obinutuzumab without and with zanubrutinib at an RP2D dose to further define the safety profile.","label":"Sonrotoclax + Zanubrutinib Combination Therapy Dose Expansion: Part 6","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Mature B-Cell Malignancies"],"enrollment":{"count":437,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sonrotoclax","otherNames":["BGB-11417"],"type":"DRUG"},{"name":"Zanubrutinib","otherNames":["BGB-3111"],"type":"DRUG"},{"name":"Obinutuzumab","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-22","lead_sponsor":"BeOne Medicines","official_title":"A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Number of Participants Experiencing Serious Adverse Events (SAEs)","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Number of Participants Experiencing Adverse Events (AEs) leading to discontinuation of Sonrotoclax","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3: Maximum Tolerated Dose (MTD) of Sonrotoclax","timeFrame":"Up to approximately 2 months"},{"measure":"Part 1, Part 3, Part 5: RP2D of Sonrotoclax","timeFrame":"Day 1 to last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3, Part 5: Number of participants experiencing tumor lysis syndrome (TLS) relevant events","timeFrame":"Up to 30 days after the last dose of study drug, an average of 18 months"},{"measure":"Part 1, Part 3, Part 5: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs","timeFrame":"Up to approximately 2 months"}],"references":[],"start_date":{"date":"2020-03-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies","url":"https://clinicaltrials.gov/study/NCT04277637"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bgb-11417-101-nct04277637"}